Progress and prospects: Advancements in retroviral vector design, generation, and application

Human Gene Therapy

Volumn 22, Issue 10, 2011, Pages 1171-1174

  Mukherjee, Sayandip ^a   Thrasher, Adrian J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR;

EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GOOD MANUFACTURING PRACTICE; HUMAN; LENTIVIRINAE; NOTE; RISK ASSESSMENT; RNA INTERFERENCE; ULTRACENTRIFUGATION; WESTERN BLOTTING;

GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; LENTIVIRUS;

EID: 80155139422     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.2523     Document Type: Note

References (40)

1. Ageichik, A., Buchholz, C.J., and Collins, M.K. (2011). Lentiviral vectors targeted to MHC II are effective in immunization. Hum. Gene Ther. 22, 1249-1254.
2. Broussau, S., Jabbour, N., Lachapelle, G., et al. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 16, 500-507. (Pubitemid 351314989)
3. Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553. (Pubitemid 34408678)
4. Bushman, F., Lewinski, M., Ciuffi, A., et al. (2005). Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3, 848-858. (Pubitemid 41693180)
5. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322.
6. Cockrell, A.S., Ma, H., Fu, K., et al. (2006). A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 14, 276-284. (Pubitemid 43964495)
7. Fire, A., Xu, S., Montgomery, M.K., et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811. (Pubitemid 28099681)
8. Fish, R.J., and Kruithof, E.K. (2004). Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol. Biol. 5, 9.
9. Froelich, S., Tai, A., and Wang, P. (2010). Lentiviral vectors for immune cell targeting. Immunopharmacol. Immunotoxicol. 32, 208-218.
10. Froelich, S., Tai, A., Kennedy, K., et al. (2011). Pseudotyping lentiviral vectors with Aura virus envelopeglycoproteins for DCV-SIGN-mediated transduction of dendritic cells. Hum. Gene Ther. 22, 1281-1291.
11. Galimi, F., Saez, E., Gall, J., et al. (2005). Development of ecdysone-regulated lentiviral vectors. Mol. Ther. 11, 142-148. (Pubitemid 40012008)
12. Giry-Laterrière, M., Cherpin, O., Kim, Y.-S., et al. (2011). Polyswitch lentivectors: All-in-one' lentiviral vectors for druginducible gene expression, live selection, and recombination cloning. Hum. Gene Ther. 22, 1255-1267.
13. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547-5551.
14. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
15. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
16. Ikeda, Y., Takeuchi, Y., Martin, F., et al. (2003). Continuous hightiter HIV-1 vector production. Nat. Biotechnol. 21, 569-572. (Pubitemid 36532025)
17. Joo, K.I., and Wang, P. (2008). Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther. 15, 1384-1396.
18. Kim, D.H., Behlke, M.A., Rose, S.D., et al. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226. (Pubitemid 40255333)
19. Kutner, R.H., Zhang, X.Y., and Reiser, J. (2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 4, 495-505.
20. Li, X.-Y., Lai, Y.-K., Zhang, J.-F., et al. (2011). Lentivirusmediated RNA interference targeting Bax inhibitor-1 suppresses ex vivo cell proliferation and in vivo tumor growth of nasopharyngeal carcinoma. Hum Gene Ther. 22, 1201-1208.
21. Lizee, G., Gonzales, M.I., and Topalian, S.L. (2004). Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 15, 393-404. (Pubitemid 38469781)
22. Matrai, J., Chuah, M.K., and Vandendriessche, T. (2010). Recent advances in lentiviral vector development and applications. Mol. Ther. 18, 477-490.
23. Merten, O.W., Charrier, S., Laroudie, N., et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343-356.
24. Metelo, J., Ward, N., Thrasher, A.J., and Burns, S.O. (2011). Lentivectors are efficient tools to manipulate the dendritic cell cytoskeleton. Cytoskeleton 68, 434-445.
25. Morizono, K., Ku, A., Xie, Y., et al. (2010). Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J. Virol. 84, 6923-6934.
26. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
27. Papadaki, M., Konstantina Siapati, E., and Vassilopoulos, G. (2011). A foamy virus vector system for stable and efficient RNAi expression in mammalian cells. Hum. Gene Ther. 22, 1293-1303.
28. Park, T.S., Rosenberg, S.A., and Morgan, R.A. (2011). Treating cancer with genetically engineered T cells. Trends Biotechnol. [Epub ahead of print; DOI: 10.1016/j.biotech.2011.04.009].
29. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
30. Schambach, A., and Baum, C. (2008). Clinical application of lentiviral vectors: Concepts and practice. Curr. Gene Ther. 8, 474-482.
31. Schroers, R., Sinha, I., Segall, H., et al. (2000). Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 1, 171-179.
32. Sirin, O., and Park, F. (2003). Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristoneinducible system. Gene 323, 67-77. (Pubitemid 37501086)
33. Soneoka, Y., Cannon, P.M., Ramsdale, E.E., et al. (1995). A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23, 628-633.
34. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204.
35. Throm, R.E., Ouma, A.A., Zhou, S., et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104-5110.
36. Trono, D. (2000). Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther. 7, 20-23. (Pubitemid 30077144)
37. Vigna, E., Cavalieri, S., Ailles, L., et al. (2002). Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther. 5, 252-261. (Pubitemid 34211220)
38. Xu, K., Ma, H., McCown, T.J., et al. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104. (Pubitemid 32509810)
39. Yang, L., Yang, H., Rideout, K., et al. (2008). Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26, 326-334. (Pubitemid 351355129)
40. Zarei, S., Leuba, F., Arrighi, J.F., et al. (2002). Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol. 109, 988-994. (Pubitemid 34634310)